Does dapagliflozin improve glucose uptake, reduce inflammation, and promote differentiation in human epicardial adipose tissue from patients with cardiovascular disease?
Dapagliflozin demonstrates direct protective effects on human epicardial adipose tissue by improving glucose uptake, reducing inflammation, and promoting cell differentiation, suggesting a novel mechanistic pathway for its cardiovascular benefits.
Dapagliflozin increased glucose uptake, reduced the secretion of pro-inflammatory chemokines (with a beneficial effect on the healing of human coronary artery endothelial cells), and improved the differentiation of EAT cells. These results suggest a new protective pathway for this drug on EAT from patients with cardiovascular disease.
Díaz‐Rodriguez et al. (Fri,) studied this question.